Physician profile
Sara E Curtis
NPI 1407251424
$6,892.24
in general payments reported to CMS, 2019-2025
23 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $992 · 2022: $843 · 2023: $1,683 · 2024: $1,795 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,057.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,325.05 | 2021-2025 | Leqvio |
| Amgen INC. | $966.29 | 2021-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $792.63 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $659.37 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $508.97 | 2021-2025 | Brilinta, Lokelma, Farxiga |
| Pfizer INC. | $383.35 | 2021-2025 | |
| Boston Scientific Corporation | $353.92 | 2021-2025 | Watchman Access System, Watchman Flx |
| Scpharmaceuticals INC. | $343.78 | 2024-2025 | |
| Medtronic, INC. | $294.14 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $225.86 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.85 | 2021-2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $172.98 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $135.91 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $135.68 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $128.45 | 2021-2025 | Verquvo, Capvaxive |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $54.29 | 2021-2022 | |
| Amarin Pharma, INC. | $43.29 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $40.45 | 2025 | Opsumit, Uptravi |
| Alnylam Pharmaceuticals INC. | $32.76 | 2025 | |
| Elutia, INC. | $19.97 | 2021 | |
| Irhythm Technologies, INC. | $19.83 | 2021 | |
| Novo Nordisk INC | $18.50 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $16.92 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.